Surrey Heartlands

Joint Formulary & PAD

Dabigatran etexilate - VTE treatment and prevention (children)

You are here : Home > Formulary Search > Dabigatran etexilate - VTE treatment and prevention (children)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

See narrative
Formulations :
  • Sachets (granules)
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
NFD2
Restrictions / Comments :
Important

Not assessed for inclusion on the formulary. Contact pharmacy team for advice on making an application.

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Dabigatran etexilate
Indication :
VTE treatment and prevention (children)
Group Name :
Keywords :
Brand Names Include :
Pradaxa granules
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Other Indications

Below are listed other indications that Dabigatran etexilate is used to treat.

Other Drugs

Below are listed other drugs that are used to treat VTE treatment and prevention (children).

  • No records returned.

Committee Recommendations (1)

23 Jan 24 - Not Set

This drug has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.